Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
$5.64
-$0.05(-0.80%)
At close: 4:00 PM EST
$5.64
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$3.38 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)3.58M
Market Cap
$1.73B
Enterprise Value$1.88B
Total Cash (Recent Filing)$260.04M
Total Debt (Recent Filing)$225.95M
Price to Earnings (P/E)61.4
Beta0.85
Next Earnings
Mar 03, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding307,070,280
10 Day Avg. Volume4,000,434
30 Day Avg. Volume3,580,941
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-22.39
Price to Sales (P/S)6.18
P/FCF Ratio53.77
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue5.98
Enterprise Value/Gross Profit7.95
Enterprise Value/Ebitda25.66
Forecast
1Y Price Target
$9.30Price Target Upside64.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Autoinjector Regulatory ProgressFDA acceptance and potential approval of the Furoscix autoinjector could allow IV-equivalent diuretic dosing via subcutaneous delivery, broadening clinical use and adoption.
Pediatric Label ExpansionApproval of an Afrezza pediatric label could open access to pediatric insulin patients and enable easier switching of children on insulin pumps, expanding the product's addressable market.
Pipeline Diversification And Clinical ProgressEarly clinical progress for inhaled nintedanib, with planned Phase 2 testing, signals meaningful pipeline diversification that could drive future upside beyond core products.
Bears Say
Clinical Program DiscontinuationDiscontinuation of the MNKD-101 program due to futility reduces pipeline depth and may prompt the market to discount the value of related development efforts.
Commercial And Regulatory Execution RiskCommercial execution challenges and regulatory setbacks could limit uptake of label expansions and delay when revenue benefits are realized, weighing on near-term forecasts.
Partner Concentration RiskDependence on a commercialization partner for a major product could reduce company control over marketing and pricing, limiting the firm's ability to capture full economic value.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $3.38 and its highest was $6.51 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $1.73B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Mar 03, 2026 which is in 32 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Nov 05, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.019 by $0.011.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is 0.02.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 307,070,280 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of $0.03 in its last earnings report, beating expectations of $0.019. Following the earnings report the stock price went up 10.584%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.30 (64.89% Upside)
$9.30 (64.89% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.56%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue performance driven by Tyvaso DPI and Afrezza, alongside strategic growth initiatives such as the acquisition of scPharmaceuticals. However, challenges such as a decline in VGo revenue and increased SG&A expenses were noted. Overall, the positive aspects of revenue growth and strategic acquisitions outweighed the lowlights.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$9.30
▲(64.89% Upside)
Technical Analysis
Ownership Overview
2.92% Insiders
10.93% Mutual Funds
0.97% Other Institutional Investors
69.20% Public Companies and Individual Investors